mTORC1/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAs

Gizelka David‐West(Westchester Medical Center), Robert J. Schneider(NYU Langone’s Laura and Isaac Perlmutter Cancer Center)
Oncotarget
September 4, 2018
Cited by 50


Related Papers